Evaluation of the Antiviral Activity of Tabamide A and Its Structural Derivatives against Influenza Virus
- PMID: 38139128
- PMCID: PMC10744247
- DOI: 10.3390/ijms242417296
Evaluation of the Antiviral Activity of Tabamide A and Its Structural Derivatives against Influenza Virus
Abstract
Influenza viruses cause severe endemic respiratory infections in both humans and animals worldwide. The emergence of drug-resistant viral strains requires the development of new influenza therapeutics. Tabamide A (TA0), a phenolic compound isolated from tobacco leaves, is known to have antiviral activity. We investigated whether synthetic TA0 and its derivatives exhibit anti-influenza virus activity. Analysis of structure-activity relationship revealed that two hydroxyl groups and a double bond between C7 and C8 in TA0 are crucial for maintaining its antiviral action. Among its derivatives, TA25 showed seven-fold higher activity than TA0. Administration of TA0 or TA25 effectively increased survival rate and reduced weight loss of virus-infected mice. TA25 appears to act early in the viral infection cycle by inhibiting viral mRNA synthesis on the template-negative strand. Thus, the anti-influenza virus activity of TA0 can be expanded by application of its synthetic derivatives, which may aid in the development of novel antiviral therapeutics.
Keywords: antiviral drugs; influenza viruses; structural derivatives; tabamide A; viral RNA synthesis.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10744247/bin/ijms-24-17296-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10744247/bin/ijms-24-17296-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10744247/bin/ijms-24-17296-g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10744247/bin/ijms-24-17296-g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10744247/bin/ijms-24-17296-g005.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10744247/bin/ijms-24-17296-g006.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10744247/bin/ijms-24-17296-g007.gif)
Similar articles
-
Evaluation of Antiviral Activity of Gemcitabine Derivatives against Influenza Virus and Severe Acute Respiratory Syndrome Coronavirus 2.ACS Infect Dis. 2023 Apr 14;9(4):1033-1045. doi: 10.1021/acsinfecdis.3c00034. Epub 2023 Mar 13. ACS Infect Dis. 2023. PMID: 36912867 Free PMC article.
-
Exploring the Inhibitory Effect of AgBiS2 Nanoparticles on Influenza Viruses.Int J Mol Sci. 2023 Jun 16;24(12):10223. doi: 10.3390/ijms241210223. Int J Mol Sci. 2023. PMID: 37373369 Free PMC article.
-
Perspective of Use of Antiviral Peptides against Influenza Virus.Viruses. 2015 Oct 20;7(10):5428-42. doi: 10.3390/v7102883. Viruses. 2015. PMID: 26492266 Free PMC article. Review.
-
Pyrazole compound BPR1P0034 with potent and selective anti-influenza virus activity.J Biomed Sci. 2010 Feb 23;17(1):13. doi: 10.1186/1423-0127-17-13. J Biomed Sci. 2010. PMID: 20178582 Free PMC article.
-
Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance.Curr Med Chem. 2018;25(38):5115-5127. doi: 10.2174/0929867324666170920165926. Curr Med Chem. 2018. PMID: 28933281 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous